Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198146
Status:
COMPLETED
Last Update Posted:
2020-08-11
First Post:
2005-09-12
Brief Title:
Prevention of Diabetes Progression Trial PDPT
Sponsor:
Indiana University School of Medicine
Organization:
Indiana University
Study Overview
Official Title:
PD InitiatedPrevention of Diabetes Progression Trial PDPT ZEN119
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes Additional purposes of the study are to investigate the amount of drug in the children how quickly it is eliminated from the blood and analyze the effect of the drug on the immune reaction to diabetes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None